Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacotherapy Pub Date : 2024-10-23 DOI:10.1002/phar.4619
Ye-Qian He, Yu-Qing Wei, Guang-Ming Huang, Guo-Ping Liu, Zhong-Qiu Lin, Tao-Tao Liu, Xia Jiang, Jie-Jiu Lu
{"title":"Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis.","authors":"Ye-Qian He, Yu-Qing Wei, Guang-Ming Huang, Guo-Ping Liu, Zhong-Qiu Lin, Tao-Tao Liu, Xia Jiang, Jie-Jiu Lu","doi":"10.1002/phar.4619","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low-density lipoprotein cholesterol (LDL-C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed to investigate sex differences in the efficacy of evolocumab using real-world data.</p><p><strong>Method: </strong>Data were collected from the First Affiliated Hospital of Guangxi Medical University. A total of 416 eligible patients were selected from 1463 patients treated with evolocumab for secondary prevention. Clinical data, including individual characteristics and lipids profiles, were recorded. Propensity score matching (PSM) was used to control for potential confounders, with covariates including age, body mass index, smoking status, and diabetes. All eligible participants were propensity-matched 1:1 for female versus male with a match tolerance of 0.02. The efficacy of evolocumab in females and males was compared by PSM-adjusted analysis.</p><p><strong>Results: </strong>In the PSM analysis, a significant difference was found in the relative percentage reduction of LDL-C between females and males (-42.7% vs. -54.4%, p < 0.001). In addition, the absolute LDL-C reduction was lower in females compared to males (interquartile range: -1.5 [-2.2, -0.8] mmol/L vs. -1.9 [-2.5, -1.0] mmol/L, p = 0.018). The rate of target LDL-C attainment was lower in females than in males after treatment with evolocumab (21.6% vs. 39.8%, p = 0.009).</p><p><strong>Conclusion: </strong>These results suggest that males have a better response to evolocumab in term of LDL-C reduction compared to females.</p>","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.4619","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low-density lipoprotein cholesterol (LDL-C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed to investigate sex differences in the efficacy of evolocumab using real-world data.

Method: Data were collected from the First Affiliated Hospital of Guangxi Medical University. A total of 416 eligible patients were selected from 1463 patients treated with evolocumab for secondary prevention. Clinical data, including individual characteristics and lipids profiles, were recorded. Propensity score matching (PSM) was used to control for potential confounders, with covariates including age, body mass index, smoking status, and diabetes. All eligible participants were propensity-matched 1:1 for female versus male with a match tolerance of 0.02. The efficacy of evolocumab in females and males was compared by PSM-adjusted analysis.

Results: In the PSM analysis, a significant difference was found in the relative percentage reduction of LDL-C between females and males (-42.7% vs. -54.4%, p < 0.001). In addition, the absolute LDL-C reduction was lower in females compared to males (interquartile range: -1.5 [-2.2, -0.8] mmol/L vs. -1.9 [-2.5, -1.0] mmol/L, p = 0.018). The rate of target LDL-C attainment was lower in females than in males after treatment with evolocumab (21.6% vs. 39.8%, p = 0.009).

Conclusion: These results suggest that males have a better response to evolocumab in term of LDL-C reduction compared to females.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evolocumab 降低 LDL-C 反应的性别差异:倾向得分匹配分析
背景:研究表明,前蛋白转化酶亚基酶/kexin 9 型抑制剂(PCSK9i)可通过降低低密度脂蛋白胆固醇(LDL-C)改善心血管预后。然而,evolocumab疗效的性别差异仍不清楚。本研究旨在利用真实世界的数据调查依维莫司疗效的性别差异:方法:数据来自广西医科大学第一附属医院。方法:数据来自广西医科大学第一附属医院,从1463名接受evolocumab二级预防治疗的患者中筛选出416名符合条件的患者。记录临床数据,包括个体特征和血脂概况。采用倾向得分匹配法(PSM)控制潜在的混杂因素,协变量包括年龄、体重指数、吸烟状况和糖尿病。所有符合条件的参与者均按女性与男性 1:1 的比例进行倾向匹配,匹配容差为 0.02。通过PSM调整分析比较了evolocumab对女性和男性的疗效:结果:在 PSM 分析中发现,女性和男性的低密度脂蛋白胆固醇相对降低百分比存在显著差异(-42.7% vs. -54.4%,p 结论:这些结果表明,男性对低密度脂蛋白胆固醇的降低效果更好:这些结果表明,与女性相比,男性对 evolocumab 降低 LDL-C 的反应更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacotherapy
Pharmacotherapy 医学-药学
CiteScore
7.80
自引率
2.40%
发文量
93
审稿时长
4-8 weeks
期刊介绍: Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.
期刊最新文献
Cannabinoids for obstructive sleep apnea: A systematic review. ECLIPSES: Early initiation of sodium glucose cotransporter-2 inhibitors for cardiovascular protection in patients with type 2 diabetes following acute coronary syndrome and subsequent coronary artery bypass graft surgery. Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis. Association between gastroprotective agents and acute kidney injury in patients receiving non-steroidal anti-inflammatory drugs: Analysis of a Japanese hospital-based database. Albuminuria-based stratification of end-stage kidney disease progression and mortality with sodium-glucose cotransporter 2 inhibitors (SGLT2i): A retrospective cohort study in type 2 diabetes and chronic kidney disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1